Request Demo

Last update 26 May 2025

Carotuximab

Last update 26 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Carotuximab (USAN/INN), Chimeric anti-CD105 antibody, Chimeric Antibody TRC-105

+ [6]

Target

ENG

Action

inhibitors

Mechanism

ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors

Therapeutic Areas

NeoplasmsUrogenital DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Metastatic castration-resistant prostate cancerHormone receptor positive HER2 negative breast cancerLocally advanced breast cancer+ [3]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBladder Cancer+ [23]

Originator Organization

Roswell Park Comprehensive Cancer Center

TRACON Pharmaceuticals, Inc.

Active Organization

Novartis Pharmaceuticals Corp.

Cedars-Sinai Medical Center

Kairos Pharma Ltd.

+ [1]

Inactive Organization

Ambrx, Inc.

Santen Pharmaceutical Co., Ltd.

License Organization

Kairos Pharma Ltd.

Santen Pharmaceutical Co., Ltd.

TRACON Pharmaceuticals, Inc.

+ [2]

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 319922187H

Source: *****

Sequence Code 319922188L

Source: *****

Clinical Trials associated with Carotuximab

NCT05534646

/ RecruitingPhase 2IIT

Phase II Study of Apalutamide with Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to apalutamide that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

Start Date27 Dec 2023

Sponsor / Collaborator

Cedars-Sinai Medical Center

NCT05401110

/ RecruitingPhase 1IIT

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

Start Date15 Sep 2023

Sponsor / Collaborator

Cedars-Sinai Medical Center

NCT02520063

/ Active, not recruitingPhase 1/2IIT

A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer

This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.

Start Date23 Feb 2019

Sponsor / Collaborator

The University of Alabama at Birmingham

[+2]

100 Clinical Results associated with Carotuximab

100 Translational Medicine associated with Carotuximab

100 Patents (Medical) associated with Carotuximab

Literatures (Medical) associated with Carotuximab

01 Mar 2025·LIFE SCIENCES

Anti-Endoglin monoclonal antibody prevents the progression of liver sinusoidal endothelial inflammation and fibrosis in MASH

Article

Author: Igreja Sa, Ivone Cristina ; Havelek, Radim ; Fikrova, Petra ; Tripska, Katarina ; Eissazadeh, Samira ; König, Matthias ; Nemeckova, Ivana ; Mohammadi, SeyedehNiloufar ; Micuda, Stanislav ; Vasinova, Martina ; Rathouska, Jana Urbankova ; Theuer, Charles ; Nachtigal, Petr

Liver sinusoidal endothelial inflammation/dysfunction and fibrosis are a crucial part of Metabolic Dysfunction Associated Steatohepatitis (MASH) development. TRC105 and M1043 are anti-endoglin (ENG) monoclonal antibodies that bind ENG. In this study, we hypothesized that treatment with anti-ENG antibodies would prevent the progression of LSECs inflammation and fibrosis in vivo and in vitro. MASH was induced in male C57BL/6 mice fed a choline-deficient L-amino acid-defined high-fat diet (CDAA-HFD) for 4 or 8 weeks. In the rescue study, mice were divided into three groups: a control group (chow diet), a MASH group (CDAA-HFD + IgG), and a rescue group (CDAA-HFD + M1043). Later, two groups received rat IgG1 (10 mg/kg) and M1043 (10 mg/kg). In in vitro experiments, inflammation was induced in human LSECs by ox-LDL (50 μg/mL) and treated with TRC105 (300 μg/mL). Liver sinusoidal endothelial inflammation/dysfunction in MASH animals was characterized by endothelial overexpression of ENG, VCAM-1, and ICAM-1 and reduced VE-cadherin and p-eNOS/eNOS expression. M1043 treatment prevented the overexpression of ENG, VCAM-1, and ICAM-1, the progression of liver fibrosis, and the increase of liver-to-body weight ratio. In vitro experiments with TRC105 confirmed the prevention of LSECs inflammation development by reduced ENG and VCAM-1 expression, as well as decreased THP-1 monocytic cell adhesion in ox-LDL activated LSECs. In conclusion, we demonstrate that anti-ENG antibody treatment can prevent LSECs inflammation and fibrosis progression in a MASH animal model and LSECs inflammation in vitro. Thus, we propose directly targeted ENG may represent a promising pharmacological approach for addressing LSECs inflammation and liver fibrosis.

01 Apr 2023·Breast cancer research and treatment

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

Article

Author: Acosta, Edward P ; Vaklavas, Christos ; Wei, Shi ; Stringer-Reasor, Erica M ; Grizzle, William E ; Forero-Torres, Andres ; Li, Yufeng ; Elkhanany, Ahmed M ; Ryan, Kevin J ; Theuer, Charles P ; Yang, Eddy S

Abstract:

Purpose:

In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative letrozole, everolimus, and carotuximab, a monoclonal antibody targeting endoglin, in nonmetastatic breast cancer.

Methods:

Eligible patients had newly diagnosed, stage 2 or 3, hormone receptor-positive and Her2/neu-negative breast cancer. Patients received escalating doses of everolimus; the dose of letrozole and carotuximab were fixed at 2.5 mg PO daily and 15 mg/kg intravenously every 2 weeks, respectively. The primary objective was to determine the safety and tolerability of the combination. Secondary objectives included pharmacokinetic and pharmacodynamic studies and assessments of antitumor activity.

Results:

Fifteen patients enrolled. The recommended phase 2 dose of everolimus in combination with letrozole and carotuximab was 10 mg PO daily. The most frequent adverse events were headache (67%), fatigue (47%), facial flushing and swelling (47%), gingival hemorrhage (40%), epistaxis (33%), nausea and vomiting (27%). Headache constituted a dose-limiting toxicity. At least two signs of mucocutaneous telangiectasia developed in 92% of patients. Carotuximab accumulated in the extravascular space and accelerated the biodistribution and clearance of everolimus. All patients had residual disease. Gene expression analyses were consistent with downregulation of genes involved in proliferation and DNA repair. Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy.

Conclusion:

Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab.

Trial registration:

This trial is registered with ClinicalTrials.gov (Identifier: NCT02520063), first posted on August 11, 2015, and is active, not recruiting.

01 Jan 2023·Frontiers in medicine

Endoglin and squamous cell carcinomas.

Article

Author: Harryvan, Tom J ; Boonstra, Jurjen J ; Hakuno, Sarah K ; Janson, Stefanus G T ; Dinjens, Winand N M ; de Jonge-Muller, Eveline ; de Graaf, Manon ; Hawinkels, Lukas J A C ; Slingerland, Marije ; Trietsch, Marjolijn D ; Crobach, Stijn

Despite the fact that the role of endoglin on endothelial cells has been extensively described, its expression and biological role on (epithelial) cancer cells is still debatable. Especially its function on squamous cell carcinoma (SCC) cells is largely unknown. Therefore, we investigated SCC endoglin expression and function in three types of SCCs; head and neck (HNSCC), esophageal (ESCC) and vulvar (VSCC) cancers. Endoglin expression was evaluated in tumor specimens and 14 patient-derived cell lines. Next to being expressed on angiogenic endothelial cells, endoglin is selectively expressed by individual SCC cells in tumor nests. Patient derived HNSCC, ESCC and VSCC cell lines express varying levels of endoglin with high interpatient variation. To assess the function of endoglin in signaling of TGF-β ligands, endoglin was overexpressed or knocked out or the signaling was blocked using TRC105, an endoglin neutralizing antibody. The endoglin ligand BMP-9 induced strong phosphorylation of SMAD1 independent of expression of the type-I receptor ALK1. Interestingly, we observed that endoglin overexpression leads to strongly increased soluble endoglin levels, which in turn decreases BMP-9 signaling. On the functional level, endoglin, both in a ligand dependent and independent manner, did not influence proliferation or migration of the SCC cells. In conclusion, these data show endoglin expression on individual cells in the tumor nests in SCCs and a role for (soluble) endoglin in paracrine signaling, without directly affecting proliferation or migration in an autocrine manner.

News (Medical) associated with Carotuximab

28 Apr 2025

·www.businesswire.com

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” and will be presented on June 2. John Yu, M.D., Kairos CEO commented, “We look forward to the opportunity to continue to share data regarding our platform assets at one of the most prestigious oncology meetings in the world. We believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing our findings with the medical and scientific communities.” About Kairos Pharma, Ltd. Based in Los Angeles, California, Kairos Pharma, Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the trials aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com. CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

Phase 2ASCOPhase 1

24 Apr 2025

·www.businesswire.com

Kairos Pharma Ltd. Provides Letter to Stockholders

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: To our valued stockholders, As we reflect on the Company’s progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds. We currently have two ongoing clinical trials for our lead drug, ENV105, which is being tested in patients with prostate cancer in a Phase 2 trial and is being tested in a Phase 1 trial for patients with a type of lung cancer (called EGFR-dependent non-small cell lung cancer). As part of these trials, we are also identifying and confirming biomarkers to identify patients for whom this combined therapy may prove most effective. Our CSO Dr. Neil Bhowmick’s lab received $876,000 from the Department of Defense to support a biomarker study for lung cancer patients responsive to ENV105. In addition to our long-standing, close relationship with Cedars Sinai Hospital in Los Angeles, where we are conducting both trials, we have also expanded the prostate trial sites to the University of Utah and City of Hope. We are aiming to be able to discuss safety and interim efficacy results toward the end of the second quarter 2025. We are also continuing our development work for our proprietary immune response compounds, including KROS101, designed to treat cancers by increasing the killer T cell population while decreasing the suppressor Treg population. We have reported some exciting data on this GITR ligand small molecule agonist at American Association for Cancer Research meetings, the Society for Immunotherapy of Cancer meeting, and at the upcoming American Society of Clinical Oncology meeting. There remains significant unmet medical needs in both cancer and inflammation. We believe our research will open new paths to help address these serious conditions. Each of the indications we seek to address represent multi-billion-dollar markets. Further, we continue to receive non-dilutive government grants to support research in several of our programs, even in an environment where these types of grants are in jeopardy of drying up due to the macro political environment. Finally, we have a robust intellectual property portfolio that we believe will provide significant protection into the 2030s. We now have significant research analyst coverage through several investment banks, including EF Hutton, D. Boral, Rodman and Renshaw, Maxim, and HC Wainwright. Further, we will be participating in the D. Boral Healthcare Conference in May and the HC Wainwright Healthcare Conference in September. Despite recent economic headwinds, we remain financially strong due to our recent private placement and judicious use of funds with non-dilutive funding. Thank you for your continued support and confidence in our mission. We look forward to providing you with regular updates on our progress as we move forward. Sincerely, John Yu, M.D. CEO, Kairos Pharma About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the trials aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com. CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

Phase 2ASCOPhase 1Immunotherapy

17 Apr 2025

·www.businesswire.com

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense (“DoD”) is providing $876,000 to advance a strategy to identify patients that are starting to develop resistance at an early stage. The grant was awarded to identify biomarkers for the Company’s clinical study to address the major challenge in achieving a lasting cure for lung cancer patients. The grant was awarded to Cedars-Sinai Medical Center to support research in Dr. Neil Bhowmick’s laboratory to identify biomarkers of patients with non-small cell carcinoma who have developed resistance to Osimertinib. This will provide a means to identify those patients who will benefit from ENV105. Kairos Pharma CEO John Yu, M.D., stated, “Peer-reviewed support like this DoD grant is a testament to the sound scientific basis for our current Phase 1 trial in lung cancer patients receiving ENV105. It is particularly gratifying in the current environment, in which these grants are harder to achieve, underscoring the potential for ENV105 to help ensure effective therapy in this lung cancer form common to non-smokers. Grants like this enable us to progress with our trials while minimizing expense and managing our cash burn.” The DoD grant is designed to contribute to a strategy to limit resistance to osimertinib at its most early stages, by identifying patients that would be best helped by ENV105 treatment. In the near term, the Company expects that the funded study may lead to more effective monitoring and early detection of resistance development, allowing for more timely interventions to improve overall survival and quality of life for patients. About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com. CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

Phase 1Phase 2

100 Deals associated with Carotuximab

External Link

KEGG	Wiki	ATC	Drug Bank
D11260	Carotuximab	-	DB06322

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemangiosarcoma	Phase 3	United States	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Austria	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	France	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Germany	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Italy	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Poland	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Spain	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	United Kingdom	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hormone receptor positive HER2 negative breast cancer	Phase 2	United States	Novartis Pharmaceuticals Corp.	23 Feb 2019
Hormone receptor positive HER2 negative breast cancer	Phase 2	United States	TRACON Pharmaceuticals, Inc.	23 Feb 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02520063 (CTgov)	Phase 1/2	Locally advanced breast cancer \| Hormone receptor positive HER2 negative breast cancer	15	Letrozole+Everolimus+TRC105 (Phase I Cohort 2)	aekbhlusfp = oqclzumcyt zlsrlejdvq (wgrtxdgsxi, ygmsntnnoo - zrknuxlowk) View more	-	21 Aug 2023
				Letrozole+Everolimus+TRC105 (Phase I Cohort 1)	aekbhlusfp = dgnxzlvdtp zlsrlejdvq (wgrtxdgsxi, pbkxgiglre - rlpyxpkesn) View more
NCT02979899 (TAPPAS, Pubmed) Manual	Phase 3	Hemangiosarcoma	114	TRC105+Pazopanib	pevrkkiebn(djepbsllwk) = pghaojdcjw znokivbiwb (bkudujtxlk, 2.8 - 8.3)	Positive	31 Mar 2022
				Pazopanib	pevrkkiebn(djepbsllwk) = cyifnzsroo znokivbiwb (bkudujtxlk, 2.9 - NR)
NCT03211234 (CTgov)	Phase 2	Wet age-related macular degeneration	76	Lucentis (Sham)	tbdrzpyyal(hkkpndeltl) = codfcgxpbv gzngmftzls (tddnydrenn, 8.937) View more	-	13 Jul 2021
				DE-122+Lucentis (2.0 mg DE-122)	tbdrzpyyal(hkkpndeltl) = kuaeuxvbch gzngmftzls (tddnydrenn, 11.485) View more
NCT03418324 (CTgov)	Phase 2	Prostatic Cancer \| Metastatic castration-resistant prostate cancer	11	Abiraterone+TRC105 (Arm A: TRC105 + Abiraterone)	dtyidjmvnt = xkxxhtzxsq fradwuvdtl (ngcmtnbiwe, noqyvtbyci - rvocryidjq) View more	-	30 Dec 2020
				Enzalutamide+TRC105 (Arm E: TRC105 + Enzalutamide)	dtyidjmvnt = foypkpwppy fradwuvdtl (ngcmtnbiwe, jroxxwurjz - nwqdwwwjgp) View more
NCT01806064 (TRAXAR, CTgov)	Phase 1/2	Metastatic Renal Cell Carcinoma	173	Axitinib+TRC105 (P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	pdldpfpiwf = jmmmjezxdn fthgpqoxon (ugxuuwgrhl, nvveqmlbtw - kxiuxdlzbz) View more	-	19 Oct 2020
				Axitinib+TRC105 (P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	pdldpfpiwf = nukgizpwba fthgpqoxon (ugxuuwgrhl, ilxvvsjnru - emrklvpgfm) View more
NCT02560779 (CTgov)	Phase 1/2	Hepatocellular Carcinoma \| Unresectable Hepatocellular Carcinoma	27	Carotuximab+Sorafenib (Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)	kauxiapwzq = uicyiacbyb zlehmudmzc (xiswbzkqzz, qwhvabgsyc - wrquvkevnv) View more	-	17 Jul 2020
				Carotuximab+Sorafenib (Carotuximab (10 mg/kg Weekly) Plus Sorafenib)	kauxiapwzq = ccpcicfowf zlehmudmzc (xiswbzkqzz, hygeuoxknw - byjzbviwsa) View more
NCT03181308 (CTgov)	Phase 1	metastatic non-small cell lung cancer	11	Nivolumab+TRC105 (8 mg/kg TRC105 + Nivolumab)	teyzlgycwn = diuawrizhk blseurfyku (rqjrjhroju, gzdyulhizz - iqjqwpalwy) View more	-	24 Jun 2020
				Nivolumab+TRC105 (10 mg/kg TRC105 + Nivolumab)	teyzlgycwn = bklueajxaz blseurfyku (rqjrjhroju, ishmmftmct - fmcwwvdcnk) View more
NCT02979899 (TAPPAS, CTgov)	Phase 3	Hemangiosarcoma	128	Votrient	wtclehkudc(yfzhmcontp) = gvyjxxdloi bpwpmznfvl (wnwcqykjii, hnheuvfecn - zyzaoqxmhp) View more	-	12 May 2020
NCT01975519 (CTgov)	Phase 1/2	Sarcoma \| Locally Advanced Soft Tissue Sarcoma \| Metastatic Soft Tissue Sarcoma ... View more	111	TRC105+Pazopanib (TRC105 Plus Pazopanib)	dpffdqtcui = bozenxfjsn zgdyibgyvr (tidciosgnv, hfenkxckab - qoaydbsyyl) View more	-	12 May 2020
				TRC105+Pazopanib (8 mg/kg TRC105 + Pazopanib)	hvopgaizrk(lepsuylvsl) = onpyxeegrj zrrzjkltke (qtlaqnnjco, euqnvvbmzs - ecvdvyvdmr) View more
NCT02555306 (PAVE, CTgov)	Phase 1/2	Age Related Macular Degeneration	12	DE-122 (0.5 mg of DE-122)	aigphlqair(fkkqcnnuch) = ivpnjcppjk xllbqtspoi (qrswoevamu, 2.1) View more	-	14 Jan 2020
				DE-122 (1.0 mg of DE-122)	aigphlqair(fkkqcnnuch) = ebvuuiawvg xllbqtspoi (qrswoevamu, 5.0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis